Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Onvansertib (NMS-1286937) 是一种可口服的高选择性PLK1抑制剂,IC50值为 2 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 233 | 现货 | ||
2 mg | ¥ 326 | 现货 | ||
5 mg | ¥ 538 | 现货 | ||
10 mg | ¥ 828 | 现货 | ||
25 mg | ¥ 1,390 | 现货 | ||
50 mg | ¥ 2,160 | 现货 | ||
100 mg | ¥ 2,990 | 现货 | ||
200 mg | ¥ 4,470 | 现货 | ||
500 mg | ¥ 7,120 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 632 | 现货 |
产品描述 | Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3. |
靶点活性 | PLK1:2 nM |
体外活性 | NMS-P937 shows a broad-spectrum antiproliferative activity against different solid tumor, leukemias and lymphomas cell lines. NMS-P937 potently causes a mitotic cell-cycle arrest followed by apoptosis in A2780 cells. [2] |
体内活性 | In mice xenografted with human HCT116 colon adenocarcinoma cells, NMS-P937 (90 mg/kg/d i.v. or p.o.) shows a significant tumor growth inhibition. [1] In mice bearing HT29, Colo205 colorectal, or A2780 ovarian xenograft tumors, NMS-P937 inhibits xenograft tumor growth. In addition, NMS-P937, in combination with approved cytotoxic drugs, causes enhanced tumor regression, and prolongs survival of animals. [2] |
激酶实验 | Kinase profile: The inhibitory activity of putative kinase inhibitors and the potency of selected compounds are determined using a trans-phosphorylation assay. Specific peptide or protein substrates are trans-phosphorylated by their specific serine-threonine or tyrosine kinase, in the presence of ATP traced with 33P-γ-ATP, at optimized buffer and cofactors conditions. At the end of the phosphorylation reaction, more than 98% unlabeled ATP and radioactive ATP is captured by adding an excess of the ion exchange dowex resin; the resin then settles down to the bottom of the reaction plate by gravity. Supernatant, containing the phosphorylated substrate, is subsequently withdrawn and transferred into a counting plate, followed by evaluation by b-counting. Inhibitory potency evaluation for all the tested kinases was performed at 25 °C using a 60 min end-point assay where the concentrations of ATP and substrates are kept equal to 2 x αKm and saturated (>5 x αKm), respectively. |
细胞实验 | Cells are seeded into 96- or 384-well plates at densities ranging from 10,000 to 30,000/cm2 for adherent and 100,000/mL for nonadherent cells in appropriate medium supplemented with 10% fetal calf serum. After 24 hours, cells were treated in duplicate with serial dilutions of NMS-P937, and 72 hours later, the viable cell number was assessed by the CellTiter-Glo Assay (Promega). IC50 values were calculated with a sigmoidal fitting algorithm (Assay Explorer MDL). Experiments were carried out independently at least twice.(Only for Reference) |
别名 | NMS-P937, NMS-1286937 |
分子量 | 532.52 |
分子式 | C24H27F3N8O3 |
CAS No. | 1034616-18-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (103.28 mM)
Ethanol: 10 mg/mL (18.77 mM), Heating is recommended.
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 1.8779 mL | 9.3893 mL | 18.7786 mL | 46.9466 mL |
5 mM | 0.3756 mL | 1.8779 mL | 3.7557 mL | 9.3893 mL | |
10 mM | 0.1878 mL | 0.9389 mL | 1.8779 mL | 4.6947 mL | |
DMSO | 20 mM | 0.0939 mL | 0.4695 mL | 0.9389 mL | 2.3473 mL |
50 mM | 0.0376 mL | 0.1878 mL | 0.3756 mL | 0.9389 mL | |
100 mM | 0.0188 mL | 0.0939 mL | 0.1878 mL | 0.4695 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Onvansertib 1034616-18-6 Apoptosis Cell Cycle/Checkpoint PLK NMS 1286937 inhibit Inhibitor NMS-P 937 NMS1286937 Polo-like Kinase (PLK) NMS-P-937 NMS-P937 NMS-1286937 inhibitor